Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
7.810
+0.460 (+6.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
Next >
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
August 05, 2024
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
August 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 08, 2024
Operational complementarities expected to yield annual synergies of approximately $100 million
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
June 26, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Proposed Offering of Class A Common Stock
June 26, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
June 24, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
June 03, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 24, 2024
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur
From
Recursion Pharmaceuticals
Via
GlobeNewswire
The Next Drug You Take May be Designed By A.I.
May 14, 2024
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 13, 2024
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
May 02, 2024
Company to host public L(earnings) Call on May 9 at 5:00 pm ET
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
April 30, 2024
The grant designates Altitude Lab as a top acceleration program for biotechnology startups
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 16, 2024
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
April 02, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Publishes Annual Environmental, Social and Governance Report
March 26, 2024
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Plans to Open New Office in London
March 11, 2024
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the...
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 27, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Host Public L(earnings) Call on February 27
February 20, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Altitude Lab Startups Raise Over $120M in Capital
January 24, 2024
Launches Fellowship Grant Opportunity for Early Career Entrepreneurs
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.